The European Medicines Agency (EMA) is the European Union’s decentralized agency responsible for the scientific evaluation, authorization, and supervision of medicines for human and veterinary use. Headquartered in Amsterdam, it coordinates a network of national competent authorities and expert committees to assess quality, safety, and efficacy, and to manage post‑marketing safety through pharmacovigilance. The EMA’s centralized procedure can grant a single marketing authorization valid across EU/EEA member states.
For the chemical and pharmaceutical value chain, the EMA sets and interprets standards for active pharmaceutical ingredients and excipients, evaluates chemistry, manufacturing and controls (CMC) data, supports GMP/GDP oversight and inspections in cooperation with national authorities, and issues guidance on impurities and quality risks (including nitrosamines). It operates key regulatory platforms such as EudraVigilance for safety reporting and the Clinical Trials Information System (CTIS), and provides scientific advice and pathway designations (e.g., orphan, pediatric, and advanced therapies) that shape development and manufacturing requirements across Europe.
Single CARVYKTI infusion produced treatment-free, progression-free remissions at five years in half of early-line relapsed/refractory multiple myeloma patients.
Once-weekly somapacitan (Sogroya) receives CHMP positive opinion for children with idiopathic short stature; European Commission decision expected later this year.
CHMP backs ocrelizumab for relapsing MS in patients aged 10 and older after Phase III showed stronger lesion suppression and comparable relapse control versus fingolimod.
FDA granted priority review to an oral TYK2 inhibitor after Phase 3 data from nearly 3,000 patients showed rapid, durable skin clearance; PDUFA target Q1 2027.
FDA accepted the application for satralizumab for adult and adolescent MOGAD and granted Priority Review with a decision due 10 Jan 2027; EMA validated the MAA, EC decision expected Q3 2027.
Priority Review follows Phase III METEOROID showing 68% relapse risk reduction; FDA decision expected Jan 10, 2027; EMA validated the MOGAD filing with EC decision due Q3 2027.
Phase 3b data indicate a single Bexsero booster at age 10+ boosts immunity in those primed in infancy; full study results will be presented at IPNC in September.
Phase 2 data show FcRn blocker nipocalimab reduced SLE activity versus placebo, with larger benefit in autoantibody‑positive patients and no new safety signals.
